Supernus Pharmaceuticals, Inc. announced Intangible asset impairment charges for the quarter ended December 31, 2023. For the quarter, the company reported Intangible asset impairment charges of $20,189,000.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.07 USD | -1.71% | +2.07% | -6.29% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.29% | 1.51B | |
+19.29% | 80.67B | |
+13.63% | 9.17B | |
-15.14% | 4.86B | |
+46.88% | 4.55B | |
+15.70% | 4.34B | |
+10.89% | 2.38B | |
-27.88% | 2.2B | |
+15.73% | 2.1B | |
-43.02% | 1.86B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023